Clinical Trial Results
Search
Dr. Marc Bonaca and Dr. C Michael Gibson discuss: When is the world ready for Asymptomatic CAD Screening?
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Dr. Danielle Belardo and Dr. C. Michael Gisbon discuss: The Target is the Plaque: Stabilization, Regression, and the Role of Imaging and AI in Modern CAD Management
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Masri and Dr. C. Michael Gibson discuss: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Hofmann and Dr. Gibson discuss HELP-MI SWEDEHEART trial
Disclosures: TBD
Dr. Maros Ferencik and Dr. C. Michael Gibson discuss: Clinical Utility of Atherosclerosis Imaging in Symptomatic Patients: Lessons Learned from CCTA
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Dr. Kevin Alexander and Dr. C. Michael Gibson discuss: Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.